Meet FDA's Chief Scientist, Dr. Namandjé Bumpus @US

U.S. Food and Drug Administration | Meet FDA's Chief Scientist, Dr. Namandjé Bumpus @US_FDA | Uploaded 3 hours ago | Updated 3 hours ago

Module 8 – Part 6: Artificial Intelligence (AI) & Machine Learning (ML) in MIDD

Recursos disponibles para abordar el uso de cigarrillos electrónicos en los jóvenes

¿Cuál es el papel de la FDA en la regulación de los medicamentos?

Some Vaccines are too New? | FDA In Your Day Ep. 11

Advancing the Use of Complex Innovative Designs in Clinical Trials: From Pilot to Practice - Part 2

Tobacco Products Scientific Advisory Committee (TPSAC) Meeting P2 — 6/26/2024

Your Fall Vaccine Game Plan: COVID, Flu, & RSV Protection | FDA In Your Day Ep. 12

Module 7 – Case Study 3: Acceleration of Phase 2 Study through the MIDD Pilot Program

$FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic ... Listen to a soundcast of the May 29, 2024, FDA approval of Retevmo (selpercatinib) for patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.$

How does the FDA approve new drugs? (30 seconds)